Vnitr Lek 2021, 67(4):230-239 | DOI: 10.36290/vnl.2021.058

Chronic obstructive pulmonary disease: diagnosis and treatment of stable phase of disease; personalized treatment approach using phenotype features of the disease

Kristián Brat1, 2, Jaromír Zatloukal3, 4, Kateřina Neumannová5, Eva Voláková3, 4, Ondřej Kudela6, 7, Michal Kopecký6, 7, Marek Plutinský1, 2, Vladimír Koblížek6, 7
1 Klinika nemocí plicních a tuberkulózy, Fakultní nemocnice Brno
2 Lékařská fakulta Masarykovy univerzity, Brno
3 Klinika plicních nemocí a tuberkulózy, Fakultní nemocnice Olomouc
4 Lékařská fakulta Univerzity Palackého, Olomouc
5 Katedra fyzioterapie, Fakulta tělesné kultury, Univerzita Palackého, Olomouc
6 Plicní klinika, Fakultní nemocnice Hradec Králové
7 Lékařská fakulta v Hradci Králové, Univerzita Karlova

Chronic obstructive pulmonary disease (COPD) is a heterogenous condition affecting hundreds of millions of people worldwide. COPD is a major health problem associated with significant morbidity and mortality. In this review, the authors present the current concept of care for patients with COPD in the Czech Republic, along with a summary of treatment recommendations formulated by the expert group of the Czech Pneumological and Phthisiological Society. A more detailed version of the position paper was published in 2020. The aim of this work was to transform the most recent scientific knowledge into the context of daily practice in the Czech Republic. Our concept of care for patients with COPD uses a complex approach with special emphasis on individual phenotypic features of the disease. Maximal effort has been put into individualization of treatment according to the presence of certain clinical phenotypes/treatable traits with respect to current scientific knowledge.

Keywords: COPD, position paper, clinical phenotypes, treatable traits, individualized treatment, personalized medicine.

Published: June 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brat K, Zatloukal J, Neumannová K, Voláková E, Kudela O, Kopecký M, et al.. Chronic obstructive pulmonary disease: diagnosis and treatment of stable phase of disease; personalized treatment approach using phenotype features of the disease. Vnitr Lek. 2021;67(4):230-239. doi: 10.36290/vnl.2021.058.
Download citation

References

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. [Naposledy navštíveno: 7.4.2021]. Dostupné z: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf
  2. Miravitlles M, Vogelmeier C, Roche N et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016; 47(2): 625-637. Go to original source... Go to PubMed...
  3. Miravitlles M, Soler-Cataluña JJ, Calle M et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol. 2017; 53(6): 324-335. Go to original source...
  4. Koblizek V, Chlumsky J, Zindr V et al. Czech Pneumological and Phthisiological Society. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157(2): 189-201. Go to original source... Go to PubMed...
  5. Zatloukal J, Brat K, Neumannova K et al. Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020; 164(4): 325-356. Go to original source... Go to PubMed...
  6. Martin RJ, Bel EH, Pavord ID et al. Defining severe obstructive lung disease in the biologic era: an endotype-based approach. Eur Respir J. 2019; 54: 1900108. Go to original source... Go to PubMed...
  7. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016; 138(1): 16-27. Go to original source... Go to PubMed...
  8. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018; 13: 335-349. Go to original source... Go to PubMed...
  9. Singh D, Kolsum U, Brightling CE et al. ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6): 1697-700. Go to original source... Go to PubMed...
  10. Polosukhin VV, Richmond BW, Du RH et al. Secretory IgA Deficiency in Individual Small Airways Is Associated with Persistent Inflammation and Remodeling. Am J Respir Crit Care Med. 2017; 195(8): 1010-1021. Go to original source... Go to PubMed...
  11. McDonough JE, Yuan R, Suzuki M et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011; 365(17): 1567-1575. Go to original source... Go to PubMed...
  12. Elbehairy AF, Ciavaglia CE, Webb KA et al. Canadian Respiratory Research Network. Pulmonary Gas Exchange Abnormalities in Mild Chronic Obstructive Pulmonary Disease. Implications for Dyspnea and Exercise Intolerance. Am J Respir Crit Care Med. 2015; 191(12): 1384-1394. Go to original source... Go to PubMed...
  13. Garcia-Rio F, Miravitlles M, Soriano JB et al. EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010; 11: 63. Go to original source... Go to PubMed...
  14. King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015; 4(1): 68. Go to original source... Go to PubMed...
  15. Kim HC, Mofarrahi M, Hussain SN. Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008; 3(4): 637-658. Go to original source... Go to PubMed...
  16. Chen YW, Ramsook AH, Coxson HO et al. Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis. Chest. 2019; 156(6): 1092-1110. Go to original source... Go to PubMed...
  17. Lu Y, Feng L, Feng L et al. Systemic inflammation, depression and obstructive pulmonary function: a population-based study. Respir Res. 2013; 14: 53. Go to original source... Go to PubMed...
  18. Hersh CP, Make BJ, Lynch DA et al.; COPDGene and ECLIPSE Investigators. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med. 2014; 14: 164. Go to original source... Go to PubMed...
  19. Agusti A, Bel E, Thomas M et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016; 47(2): 410-419. Go to original source... Go to PubMed...
  20. Franssen FM, Alter P, Bar N et al. Personalized medicine for patients with COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2019; 14: 1465-1484. Go to original source... Go to PubMed...
  21. Bigna JJ, Kenne AM, Asangbeh SL et al. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. Lancet Glob Health. 2018; 6(2): e193-e202. Go to original source... Go to PubMed...
  22. Bui DS, Burgess JA, Lowe AJ et al. Childhood Lung Function Predicts Adult Chronic Obstructive Pulmonary Disease and Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome. Am J Respir Crit Care Med. 2017; 196(1): 39-46. Go to original source... Go to PubMed...
  23. Broström EB, Akre O, Katz-Salamon M et al. Obstructive pulmonary disease in old age among individuals born preterm. Eur J Epidemiol. 2013; 28(1): 79-85. Go to original source... Go to PubMed...
  24. Byrne AL, Marais BJ, Mitnick CD et al. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015; 32: 138-146. Go to original source... Go to PubMed...
  25. Hayden LP, Hobbs BD, Cohen RT et al.; COPDGene Investigators. Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. Respir Res. 2015; 16: 115. Go to original source... Go to PubMed...
  26. Greulich T, Nell C, Hohmann D et al. The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J. 2017; 49(1): 1600154. Go to original source... Go to PubMed...
  27. Guo F, Kuang JL. Superoxide dismutase gene polymorphisms and functional activity in chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2011; 34(6): 424-428. Go to PubMed...
  28. Houghton AM. Matrix metalloproteinases in destructive lung disease. Matrix Biol. 2015; 44-46: 167-174. Go to original source... Go to PubMed...
  29. Ding Z, Wang K, Li J et al. Association between glutathione S-transferase gene M1 and T1 polymorphisms and chronic obstructive pulmonary disease risk: A meta-analysis. Clin Genet. 2019; 95(1): 53-62. Go to original source... Go to PubMed...
  30. Miravitlles M, Dirksen A, Ferrarotti I et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α(1)-antitrypsin deficiency. Eur Respir J. 2017; 50(5): 1700610. Go to original source... Go to PubMed...
  31. Burgel PR, Laurendeau C, Raherison C et al. An attempt at modeling COPD epidemiological trends in France. Respir Res. 2018; 19(1): 130. Go to original source... Go to PubMed...
  32. Adeloye D, Chua S, Lee C et al.; Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015; 5(2): 020415. Go to original source... Go to PubMed...
  33. Koblizek V, Jarkovsky J, Dusek L, Benesova K, Svoboda M, Brat K. The Czechia COPD mortality rate declining, but total deaths increasing. Eur Respir J 2020; 56(suppl 64): 434. Go to original source...
  34. Vondra V, Malý M. Výrazný vzestup úmrtnosti na chronickou obstrukční plicní nemoc v České republice v letech 2013-2017. Studia Pneumol Phthiseol. 2019; 79(2): 43-50.
  35. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(10): 1005-1012. Go to original source... Go to PubMed...
  36. Puhan MA, Garcia-Aymerich J, Frey M et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009; 374(9691): 704-711. Go to original source... Go to PubMed...
  37. Brat K, Svoboda M, Hejduk K et al..Introducing a new prognostic instrument for long-term mortality prediction in COPD patients: the CADOT index. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020; in press. doi: 10.5507/bp.2020.035. Go to original source... Go to PubMed...
  38. Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. Ann Intern Med. 2011; 155(3): 179-191. Go to original source... Go to PubMed...
  39. Pellegrino R, Viegi G, Brusasco V et al. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5): 948-968. Go to original source... Go to PubMed...
  40. Brat K, Plutinsky M, Hejduk K et al. Respiratory parameters predict poor outcome in COPD patients, category GOLD 2017 B. Int J Chron Obstruct Pulmon Dis. 2018; 13: 1037-1052. Go to original source... Go to PubMed...
  41. Agusti A. The path to personalised medicine in COPD. Thorax. 2014; 69(9): 857-864. Go to original source... Go to PubMed...
  42. Le Rouzic O, Roche N, Cortot AB et al. Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach. Chest. 2018; 153(5): 1106-1115. Go to original source... Go to PubMed...
  43. Chalmers JD, Aliberti S, Filonenko A et al. Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis. Am J Respir Crit Care Med. 2018; 197(11): 1410-1420. Go to original source... Go to PubMed...
  44. Koblizek V, Milenkovic B, Barczyk A et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017; 49(5): 1601446. Go to original source... Go to PubMed...
  45. Kim V, Han MK, Vance GB et al.; COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011; 140(3): 626-633. Go to original source... Go to PubMed...
  46. Cheng Y, Tu X, Pan L et al. Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2069-2074. Go to original source... Go to PubMed...
  47. Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): A diagnostic challenge. Respirology. 2016; 21(3): 410-418. Go to original source... Go to PubMed...
  48. Takiguchi H, Asano K. Asthma-COPD overlap syndrome (ACOS). Nihon Rinsho. 2016; 74(5): 778-782. Go to PubMed...
  49. Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017; 12: 1401-1411. Go to original source... Go to PubMed...
  50. Polverino E, Dimakou K, Hurst J, et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. Eur Respir J. 2018; 52(3): 1800328. Go to original source... Go to PubMed...
  51. Yu Q, Peng H, Li B et al. Characteristics and related factors of bronchiectasis in chronic obstructive pulmonary disease. Medicine (Baltimore). 2019; 98(47): e17893. Go to original source... Go to PubMed...
  52. Sánchez-Muñoz G, Lopez-de-Andrés A, Hernández-Barrera V et al. Bronchiectasis in patients hospitalized with acute exacerbation of COPD in Spain: Influence of mortality, hospital stay, and hospital costs (2006-2014) according to gender. PLoS One. 2019; 14(1): e0211222. Go to original source... Go to PubMed...
  53. McDonald MN, Wouters EFM, Rutten E et al. It's more than low BMI: prevalence of cachexia and associated mortality in COPD. Respir Res. 2019; 20(1): 100. Go to original source... Go to PubMed...
  54. Kwan HY, Maddocks M, Nolan CM et al. The prognostic signifikance of wieght loss in chronic obstructive pulmonary disease - related cachexia: a prospective cohort study. J Cachexia Sarcopenia Muscle. 2019; 10(6): 1330-1338. Go to original source... Go to PubMed...
  55. Mokari-Yamchi A, Jabbari M, Sharifi A et al. Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients. Int J Chron Obstruct Pulmon Dis. 2019; 14: 2433-2440. Go to original source... Go to PubMed...
  56. Sanchez FF, Faganello MM, Tanni SE et al. Anthropometric midarm measurements can detect systemic fat-free mass depletion in patients with chronic obstructive pulmonary disease. Braz J Med Biol Res. 2011; 44(5): 453-459. Go to original source... Go to PubMed...
  57. Brat K, Svoboda M, Zatloukal J, Plutinsky M, Volakova E, Popelkova P, Novotna B, Dvorak T, Koblizek V. The relation between clinical phenotypes, GOLD groups/stages and mortality in COPD patients - a prospective multicenter study. Int J Chron Obstruct Pulmon Dis. 2021; in press. Go to original source... Go to PubMed...
  58. Ajmera M, Sambamoorthi U, Metzger A et al. Multimorbidity and COPD Medication Receipt Among Medicaid Beneficiaries With Newly Diagnosed COPD. Respir Care. 2015; 60(11): 1592-1602. Go to original source... Go to PubMed...
  59. Jantunen J, Haahtela T, Salimäki J et al. Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey. Int Arch Allergy Immunol. 2019; 179(4): 273-280. Go to original source... Go to PubMed...
  60. Spyratos D, Haidich AB, Chloros D et al. COPD screening program: What is appropriate target group population? Respiration. 2017; 94(1): 74. Go to original source... Go to PubMed...
  61. Ulrik CS, Løkke A, Dahl R et al., TOP study group. Early detection of COPD in general practice. Int J Chron Obstruct Pulmon Dis. 2011; 6: 123-127. Go to original source... Go to PubMed...
  62. Jiménez-Ruiz CA, Andreas S, Lewis KE et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J. 2015; 46(1): 61-79. Go to original source... Go to PubMed...
  63. Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. 2012; 40(6): 1545-1554. Go to original source... Go to PubMed...
  64. Tashkin DP, Celli B, Senn S et al.; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15): 1543-1554. Go to original source... Go to PubMed...
  65. Calverley PM, Anderson JA, Celli B et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8): 775-789. Go to original source... Go to PubMed...
  66. Singh D, D'Urzo AD, Donohue JF et al. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14: 2835-2848. Go to original source... Go to PubMed...
  67. Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005; 127(3): 809-817. Go to original source... Go to PubMed...
  68. Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013; 42(6): 1484-1494. Go to original source... Go to PubMed...
  69. Buhl R, Maltais F, Abrahams R et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015; 45(4): 969-979. Go to original source... Go to PubMed...
  70. Bolton CE, Bevan-Smith EF, Blakey JD et al.; British Thoracic Society Pulmonary Rehabilitation Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax. 2013; 68 Suppl 2: ii1-30. Go to original source... Go to PubMed...
  71. Spruit MA, Singh SJ, Garvey C et al.; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013; 188(8): e13-64. Go to original source... Go to PubMed...
  72. Garvey C, Bayles MP, Hamm LF et al. Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: AN OFFICIAL STATEMENT FROM THE AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY REHABILITATION. J Cardiopulm Rehabil Prev. 2016; 36(2): 75-83. Go to original source... Go to PubMed...
  73. Vytrisalova M, Hendrychova T, Touskova T et al. Breathing Out Completely Before Inhalation: The Most Problematic Step in Application Technique in Patients With Non-Mild Chronic Obstructive Pulmonary Disease. Front Pharmacol. 2019; 10: 241. Go to original source... Go to PubMed...
  74. Collins PF, Elia M, Stratton RJ. Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology. 2013; 18(4): 616-629. Go to original source... Go to PubMed...
  75. Lee RC, Wang Z, Heo M et al. Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. Am J Clin Nutr. 2000; 72(3): 796-803. Go to original source... Go to PubMed...
  76. Slater GJ, Duthie GM, Pyne DB et al. Validation of a skinfold based index for tracking proportional changes in lean mass. Br J Sports Med. 2006; 40(3): 208-213. Go to original source... Go to PubMed...
  77. Schols AM, Ferreira IM, Franssen FM et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J. 2014; 44(6): 1504-1520. Go to original source... Go to PubMed...
  78. Pison CM, Cano NJ, Chérion C et al.; IRAD Investigators. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax. 2011; 66(11): 953-960. Go to original source... Go to PubMed...
  79. Pumar MI, Gray CR, Walsh JR et al. Anxiety and depression-Important psychological comorbidities of COPD. J Thorac Dis. 2014; 6(11): 1615-1631. Go to PubMed...
  80. Bafadhel M, Peterson S, De Blas MA et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018; 6(2): 117-126. Go to original source... Go to PubMed...
  81. Pascoe S, Locantore N, Dransfield MT et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3(6): 435-442. Go to original source... Go to PubMed...
  82. Rossi A, Guerriero M, Corrado A; OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014; 15(1): 77. Go to original source... Go to PubMed...
  83. Chalmers JD, Laska IF, Franssen FME et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020; 55(6): 2000351. Go to original source... Go to PubMed...
  84. Kawamatawong T. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis. 2017; 9(4): 1144-1154. Go to original source... Go to PubMed...
  85. Bateman ED, Rabe KF, Calverley PM et al. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011; 38(3): 553-560. Go to original source... Go to PubMed...
  86. Dal Negro RW, Wedzicha JA, Iversen Met al.; RESTORE group; RESTORE study. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017; 50(4): 1700711. Go to original source... Go to PubMed...
  87. Seemungal TA, Wilkinson TM, Hurst JR et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008; 178(11): 1139-1147. Go to original source... Go to PubMed...
  88. Yamaya M, Azuma A, Takizawa H et al. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J. 2012; 40(2): 485-494. Go to original source... Go to PubMed...
  89. Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm Pharmacol Ther. 2010; 23(2): 135-144. Go to original source... Go to PubMed...
  90. Sun Y, Zhou J. New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation. Int J Chron Obstruct Pulmon Dis. 2019; 14: 1119-1125. Go to original source... Go to PubMed...
  91. Vaz Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993; 147: S40. Go to original source... Go to PubMed...
  92. ZuWallack RL, Mahler DA, Reilly D et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001; 119(6): 1661-1670. Go to original source... Go to PubMed...
  93. Ram FS, Jardin JR, Atallah A et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005; 99(2): 135-144. Go to original source... Go to PubMed...
  94. van Geffen WH, Kerstjens HAM, Slebos DJ. Emerging bronchoscopic treatments for chronic obstructive pulmonary disease. Pharmacol Ther. 2017; 179: 96-101. Go to original source... Go to PubMed...
  95. Criner GJ, Sue R, Wright S et al.; LIBERATE Study Group. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018; 198(9): 1151-1164. Go to original source... Go to PubMed...
  96. Valipour A. Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice. J Thorac Dis. 2018; 10(Suppl 23): S2780-2796. Go to original source... Go to PubMed...
  97. Herth FJ, Slebos DJ, Rabe KF et al. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation. Respiration. 2016; 91(3): 241-250. Go to original source... Go to PubMed...
  98. Shah PL, Herth FJ, van Geffen WH et al. Lung volume reduction for emphysema. Lancet Respir Med. 2017; 5(2): 147-156. Go to original source... Go to PubMed...
  99. Ricevuti G, Mazzone A, Uccelli E et al. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988; 43(8): 585-590. Go to original source... Go to PubMed...
  100. Polverino E, Goeminne PC, McDonnell MJ et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50(3): 1700629. Go to original source... Go to PubMed...
  101. Sidhu MK, Mandal P, Hill AT. Developing drug therapies in bronchiectasis. Expert Opin Investig Drugs. 2015; 24(2): 169-181. Go to original source... Go to PubMed...
  102. Ahmadi Z, Sundh J, Bornefalk-Hermansson A et al. Long-Term Oxygen Therapy 24 vs 15 h/day and Mortality in Chronic Obstructive Pulmonary Disease. PLoS One. 2016; 11(9): e0163293. Go to original source... Go to PubMed...
  103. Górecka D, Gorzelak K, Sliwiński P et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax. 1997; 52(8): 674-679. Go to original source... Go to PubMed...
  104. Dreher M, Storre JH, Schmoor C et al. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax. 2010; 65(4): 303-308. Go to original source... Go to PubMed...
  105. Liao H, Pei W, Li H et al. Efficacy of long-term noninvasive positive pressure ventilation in stable hypercapnic COPD patients with respiratory failure: a meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2977-2985. Go to original source... Go to PubMed...
  106. Windisch W, Haenel M, Storre JH et al. High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. Int J Med Sci. 2009; 6(2): 72-76. Go to original source... Go to PubMed...
  107. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008; 32(3): 796-803. Go to original source... Go to PubMed...
  108. Mannino DM, Thorn D, Swensen A et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008; 32(4): 962-969. Go to original source... Go to PubMed...
  109. Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and risks. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1935-1949. Go to original source... Go to PubMed...
  110. McNicholas WT. COPD-OSA Overlap Syndrome: Evolving Evidence Regarding Epidemiology, Clinical Consequences, and Management. Chest. 2017; 152(6): 1318-1326. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.